The Food and Drug Administration (FDA) has approved PARI’s eRapid Nebulizer System (eRapid), the first electronic nebulizer to deliver Pulmozyme (dornase alfa [recombinant human DNase]; Genentech) for ...
DUBLIN--(BUSINESS WIRE)--The "Pulmozyme" report has been added to ResearchAndMarkets.com's offering. Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by ...
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "PULMOZYME Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...
Genentech is thinking outside the traditional focus group in an effort to gain a better understanding of patient rationalization and decision-making which, in turn, is helping address the longstanding ...
RICHMOND, Va., Jan. 26, 2015 /PRNewswire/ -- The eRapid Nebulizer System (eRapid) from PARI has been approved as the first electronic nebulizer by the Food and Drug Administration to deliver Genentech ...
Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme. A ...
(From insert) Daily administration of Pulmozyme Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. In ...
Researchers from University College London (UCL), UCL Hospital (UCLH) and the Francis Crick Institute have revealed that a common drug used to treat cystic fibrosis has been shown to improve outcomes ...
Cystic fibrosis (CF) is a recessive genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR). CFTR regulates ion transport across the lung epithelia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results